Apogee Enterprises is a leader in architectural products and services, providing architectural glass, aluminum framing systems and installation services for buildings, and value-added glass and acrylic for custom picture framing and displays. Its markets include the U.S. government, offices, education, health care and hotels. It operates under 4 segments. The Architectural Glass segment & The Architectural Services segment are involved in designing, engineering, fabricating and installing walls and windows of glass constituting the outside skin of commercial and institutional buildings. Its key products are Viracon & Harmon. The Architectural Framing Systems designs, engineers and finishes the aluminium frames for window, curtainwall, storefront and entrance systems with features like energy efficiency and hurricane protection. The segment comprises Wausau Window and Wall Systems, Tubelite and Linetec. The Large-Scale Optical segment manufactures value-added glass and acrylic products....
+See More2023-07-21 10:30:00 Friday ET
Joseph Stiglitz and Andrew Charlton suggest that free trade helps promote better economic development worldwide. Joseph Stiglitz and Andrew Charlton (200
2019-05-23 10:33:00 Thursday ET
Berkeley professor and economist Barry Eichengreen reconciles the nominal and real interest rates to argue in favor of greater fiscal deficits. French econo
2018-01-09 08:33:00 Tuesday ET
BlackRock CEO Larry Fink emphasizes his key conviction that public corporations should make a positive contribution to society apart from boosting the botto
2019-06-17 11:25:00 Monday ET
To secure better economic arrangements with European Union, Jeremy Corbyn encourages Labour legislators to back a second referendum on Brexit. In recent tim
2019-04-11 07:35:00 Thursday ET
European Central Bank designs its current monetary policy reaction function and interest rate forward guidance in response to key delays in inflation conver
2025-10-31 12:26:00 Friday ET
With respect to wider weight loss treatment and obesity treatment, the global market for GLP-1 medications now grows substantially to benefit more than 1 bi